➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
Dow
Baxter
Moodys

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

DILANTIN Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Dilantin, and what generic alternatives are available?

Dilantin is a drug marketed by Upjohn, Parke Davis, and Pharmacia. and is included in four NDAs.

The generic ingredient in DILANTIN is phenytoin. There are twenty-one drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phenytoin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Dilantin

A generic version of DILANTIN was approved as phenytoin by VISTAPHARM on January 31st, 2001.

  Try it Free

US Patents and Regulatory Information for DILANTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn DILANTIN phenytoin sodium CAPSULE;ORAL 084349-001 Approved Prior to Jan 1, 1982 RX No Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Pharmacia DILANTIN phenytoin TABLET, CHEWABLE;ORAL 084427-001 Approved Prior to Jan 1, 1982 AB RX No Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Upjohn DILANTIN phenytoin sodium CAPSULE;ORAL 084349-002 Approved Prior to Jan 1, 1982 AB RX No Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Parke Davis DILANTIN phenytoin sodium INJECTABLE;INJECTION 010151-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
Dow
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.